Dengue fever is a relentless global threat, silently lurking in the shadows, ready to strike when our guard is down. But here's the shocking truth: without continuous, sustained efforts, we're fighting a losing battle. Experts unanimously agree that controlling dengue isn't just about sporadic interventions; it's a marathon, not a sprint. At a recent Asia Pacific media roundtable, Prof Ooi Eng Eong from Singapore’s DUKE-NUS Medical School shed light on this complex issue. He emphasized that infectious diseases, like dengue, operate in cycles influenced by factors such as virus transmission rates. And this is the part most people miss: if we pause our efforts, even briefly, the interval between epidemics shortens, and the risk of severe disease skyrockets. But how do we break this cycle? Ooi highlights the critical, yet often misunderstood, role of vaccination in maintaining population immunity. While mosquito control reduces transmission, it inadvertently lowers herd immunity, leaving communities vulnerable during outbreaks. Here’s where it gets controversial: some argue that focusing solely on mosquito eradication is enough, but Ooi counters that vaccination is the only way to sustain immunity while reducing transmission. This is especially crucial for adults, particularly those with chronic conditions like diabetes or heart disease, who are at higher risk of severe outcomes. But here’s the catch: vaccine hesitancy remains a hurdle. Ooi urges us to embrace available vaccines now, rather than waiting for a 'perfect' solution that may never come. Takeda, a pharmaceutical giant with over 240 years of history, is leading the charge in dengue vaccine distribution, focusing on endemic countries and public programs to ensure equitable access. Dr Derek Wallace, Takeda’s global vaccine president, stresses the importance of government collaboration and highlights their vaccine’s proven safety and efficacy across all four dengue serotypes. And this is where it gets even more intriguing: the COVID-19 pandemic has inadvertently paved the way for broader age-range vaccination strategies, benefiting dengue control. Dr Mahender Nayak, Takeda’s senior vice president, advocates for a holistic health system approach, emphasizing regional collaboration and public-private partnerships to strengthen preparedness and ensure vaccines reach those most in need. Indonesia’s pioneering provincial immunization program serves as a beacon of hope, showcasing the potential for shared learning. However, addressing vaccine hesitancy and health system readiness requires more than just education—it demands continuous collaboration and infrastructure strengthening. Now, here’s a thought-provoking question for you: With dengue affecting half the world’s population and ranking among the WHO’s top public health threats, can we afford to wait for the next outbreak? Or is it time to act decisively, combining vaccination, targeted strategies, and global cooperation to outsmart this relentless foe? Share your thoughts in the comments—let’s spark a conversation that could shape the future of dengue control.
